Form 4: Twist Bioscience Exec Sells Shares for Tax Withholding

Emily M. Leproust, CEO and Director of Twist Bioscience Corp, reported the sale of 2,265 shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

Summary

• Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corporation, has reported a transaction involving the sale of 2,265 shares of common stock.
• This sale, executed on June 8, 2026, at a price of $69.8442 per share, was to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• The transaction is described as a mandatory 'sell to cover' to satisfy tax liabilities, as elected by the issuer under its equity incentive plans, and does not represent a discretionary trade.
• Following this transaction, Leproust beneficially owns 844,607 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine administrative transaction for tax purposes rather than a strategic decision or a reflection of the executive's view on the company's future performance.

Positives

• The transaction is a standard procedure for covering tax liabilities on vested RSUs, indicating normal executive compensation and equity management.
• The 'sell to cover' mechanism ensures that tax obligations are met without requiring the executive to use personal funds for immediate payment.

Negatives

• The sale of shares, even for tax purposes, reduces the reporting person's direct ownership stake in the company.

Risks

• While this specific transaction is for tax withholding, any significant selling by insiders could be misinterpreted by the market.
• The company's reliance on equity-based compensation, as evidenced by RSU vesting and stock option grants, could be a factor in future insider selling activity.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a report of a past transaction.

Management Comments

• The sale of shares is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and does not represent discretionary trades by the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for executives and directors of publicly traded companies, particularly those with equity-based compensation. The 'sell to cover' transaction is a common method to manage tax liabilities associated with vesting RSUs and stock options, reflecting standard executive compensation practices within the biotechnology sector.

Stakeholder Impact

• Shareholders: The sale does not directly impact the company's operations or financial health, but it does reduce the reporting person's direct ownership, which is a minor point of observation.

Next Steps

• Continued monitoring of insider transactions for any patterns that may indicate changes in management's outlook on the company's performance or valuation.

Key Dates

Keywords

Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Emily M. Leproust, Twist Bioscience, CEO, Director, SEC Filing